Alnylam Pharmaceuticals
ALNY
$148.40
Share price
0.34%
Change (1 day)
-28.03%
Change (1 year)
Categories
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
Alnylam Pharmaceuticals (ALNY) - Total liabilities
Total liabilities on the balance sheet as of March 2024 : $4.04 B
According to Alnylam Pharmaceuticals 's latest financial reports the company's total liabilities are $4.04 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Alnylam Pharmaceuticals - Total liabilities on balance sheet (from 2003 to 2024)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-12-31 | $4.05 B | 9.34% |
| 2022-12-31 | $3.70 B | 21.26% |
| 2021-12-31 | $3.05 B | 27.78% |
| 2020-12-31 | $2.39 B | 149.97% |
| 2019-12-31 | $0.95 B | 250.55% |
| 2018-12-31 | $0.27 B | 19.51% |
| 2017-12-31 | $0.22 B | -33.36% |
| 2016-12-31 | $0.34 B | 181.28% |
| 2015-12-31 | $0.12 B | -15.02% |
| 2014-12-31 | $0.14 B | -4.56% |
| 2013-12-31 | $0.15 B | -2.14% |
| 2012-12-31 | $0.15 B | -6.38% |
| 2011-12-31 | $0.16 B | -30.26% |
| 2010-12-31 | $0.23 B | -22.54% |
| 2009-12-31 | $0.30 B | -13.94% |
| 2008-12-31 | $0.35 B | 19.66% |
| 2007-12-31 | $0.29 B | 658.71% |
| 2006-12-31 | $38.83 M | 6.19% |
| 2005-12-31 | $36.56 M | 83.17% |
| 2004-12-31 | $19.96 M | -67.74% |
| 2003-12-31 | $61.89 M | 198.16% |
| 2002-12-31 | $20.75 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | $54.57 B | 1,249.72% | 🇨🇭 Switzerland |
 Sanofi SNY | $57.61 B | 1,324.77% | 🇫🇷 France |
 Regeneron Pharmaceuticals REGN | $7.37 B | 82.47% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | $2.26 B | -44.03% | 🇺🇸 USA |
 Regulus Therapeutics RGLS | $9.56 M | -99.76% | 🇺🇸 USA |
 OPKO Health
OPK | $0.62 B | -84.61% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $35.35 B | 774.28% | 🇮🇱 Israel |
 Arrowhead Pharmaceuticals
ARWR | $0.45 B | -88.81% | 🇺🇸 USA |